Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Equity Average (2019 - 2025)

Historic Equity Average for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $1.0 billion.

  • Beam Therapeutics' Equity Average rose 2232.9% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 2232.9%. This contributed to the annual value of $857.4 million for FY2024, which is 0.41% changed from last year.
  • As of Q3 2025, Beam Therapeutics' Equity Average stood at $1.0 billion, which was up 2232.9% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Equity Average peaked at $1.1 billion during Q2 2025, and registered a low of $334.0 million during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $814.6 million (2022), whereas its average is $796.3 million.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 100796.15% in 2021, then plummeted by 1384.07% in 2022.
  • Quarter analysis of 5 years shows Beam Therapeutics' Equity Average stood at $840.3 million in 2021, then dropped by 13.84% to $724.0 million in 2022, then rose by 21.57% to $880.1 million in 2023, then decreased by 13.37% to $762.4 million in 2024, then soared by 32.0% to $1.0 billion in 2025.
  • Its last three reported values are $1.0 billion in Q3 2025, $1.1 billion for Q2 2025, and $928.3 million during Q1 2025.